ARDS (Aridis Pharmaceuticals) Scaled Net Operating Assets: -1.08 (As of Sep. 2023)


ARDS Aridis Pharmaceuticals Inc ARDS
12 GF Score
Price $0.00
View Full Analysis

What is Aridis Pharmaceuticals Scaled Net Operating Assets?

Aridis Pharmaceuticals ARDS 12 Scaled Net Operating Assets is -1.08 as of Sep. 2023. GuruFocus rates ARDS with a GF Score™ of 12/100.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aridis Pharmaceuticals's operating assets for the quarter that ended in Sep. 2023 was $6.50 Mil. Aridis Pharmaceuticals's operating liabilities for the quarter that ended in Sep. 2023 was $13.50 Mil. Aridis Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was $6.48 Mil. Therefore, Aridis Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2023 was -1.08.

Aridis Pharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Aridis Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aridis Pharmaceuticals Scaled Net Operating Assets Chart

Aridis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.08 -0.55 -0.58 -1.67 -0.86

Aridis Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.42 -1.90 -1.72 -0.92 -1.08

ARDS vs ARTL, REVB, FWBI: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Aridis Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aridis Pharmaceuticals Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Aridis Pharmaceuticals's Scaled Net Operating Assets falls into.


ARDS
12GF Score
Aridis Pharmaceuticals Inc ARDS
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aridis Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aridis Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(9.819-32.797)/26.796
=-0.86

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=14.695 - 4.876
=9.819

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=38.927 - 1.292 - 4.838
=32.797

Aridis Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2023 )
=(Operating Assets (Q: Sep. 2023 )-Operating Liabilities (Q: Sep. 2023 ))/Total Assets (Q: Jun. 2023 )
=(6.499-13.496)/6.482
=-1.08

where

Operating Assets(Q: Sep. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6.534 - 0.035
=6.499

Operating Liabilities(Q: Sep. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=18.336 - 0.854 - 3.986
=13.496

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -1.08 mean?
Aridis Pharmaceuticals (ARDS) has a Scaled Net Operating Assets of -1.08 as of Sep. 2023. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Aridis Pharmaceuticals and its competitors.
Is Aridis Pharmaceuticals' Scaled Net Operating Assets too high?
Aridis Pharmaceuticals' current Scaled Net Operating Assets is -1.08. Overall, Aridis Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aridis Pharmaceuticals' Scaled Net Operating Assets compare to ARTL and REVB?
Aridis Pharmaceuticals' Scaled Net Operating Assets of -1.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Aridis Pharmaceuticals and its competitors. Aridis Pharmaceuticals's current Scaled Net Operating Assets is -1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aridis Pharmaceuticals stock overvalued right now?
Aridis Pharmaceuticals (ARDS) has a current Scaled Net Operating Assets of -1.08. The current Scaled Net Operating Assets is -1.08. Aridis Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Aridis Pharmaceuticals (ARDS), the current Scaled Net Operating Assets is -1.08 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aridis Pharmaceuticals Business Description

Address 983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
12GF Score

Get the complete analysis for ARDS

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price